ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
会议论文

Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

Qin, S.; Chan, L. S.; Gu, S.; Bai, Y.; Ren, Z.; Lin, X.; Chen, Z.; Jia, W.; Jin, Y.; Guo, Y.; Sultanbaev, A. V.; Pazgan-Simon, M.; Pisetska, M.; Liang, X.; Chen, C.; Nie, Z.; Wang, L.; Cheng, A-L.; Kaseb, A.; Vogel, A.电子科技大学; 复旦大学; 安徽医科大学; 南方医科大学; 哈尔滨医科大学; 1
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)2022-9DOI: 10.1016/j.annonc.2022.08.032
85被引11阅读
引用收藏
分享
相关
加载中…
  • Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)
    Zang, M.; Li, Q.; Pang, H.; Hu, X.; Li, R.; Yuan, G.; Li, W.; Guo, Y.; Chen, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
  • Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)
    Chen, Jinzhang; Zang, Mengya; Pang, Huajin; Li, Chuanjiang; Zhao, Jianbo; Guo, Yabing; Hou, JinlinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 1
  • Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study
    Qin, Shukui; Chen, Zhendong; Fang, Weijia; Ren, Zhenggang; Xu, Ruocai; Ryoo, Baek-Yeol; Meng, Zhiqiang; Bai, Yuxian; Chen, Xiaoming; Liu, Xiufeng; Xiao, Juxiang; Ho, Gwo Fuang; Mao, Yimin; Ye, Xing; Ying, Jieer; Li, Jianfeng; Zhong, Wen Yan; Zhou, Yu; Siegel, Abby B.; Hao, ChunyiASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 2022-01-20 To 2022-01-22.被引 73
查看全部 →

会议信息

会议名称
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)
会议日期
2022-09-09 至 2022-09-13
论文集名
ANNALS OF ONCOLOGY
发表日期
2022-09
起止页码
S1401-S1402
DOI
10.1016/j.annonc.2022.08.032
资助标注
Jiangsu Hengrui Pharmaceuticals Co.Ltd & Elevar Therapeutics Inc.
收录
ISTP · SCIE

作者

  • Q

    Qin, S. (第一作者)

    nanjing univ chinese med

  • C

    Chan, L. S.

    chinese univ hong kong

查看全部 20 位作者收起作者
  • G

    Gu, S.

    hunan canc hosp

  • B

    Bai, Y.

    harbin med univ

  • R

    Ren, Z.

    fudan univ

  • L

    Lin, X.

  • C

    Chen, Z.

    2 · anhui med univ

  • J

    Jia, W.

    1 · anhui prov hosp · ustc

  • J

    Jin, Y.

    sichuan canc hosp & inst · univ elect sci & technol china

  • G

    Guo, Y.

    southern med univ

  • S

    Sultanbaev, A. V.

  • P

    Pazgan-Simon, M.

  • P

    Pisetska, M.

  • L

    Liang, X.

  • C

    Chen, C.

  • N

    Nie, Z.

  • W

    Wang, L.

  • C

    Cheng, A-L.

  • K

    Kaseb, A.

  • V

    Vogel, A.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417